Skip to Content

Posts tagged with "Drug Assays"

  • Drug Assays

    Metal Impurities Will Waste Your Time

    Here’s a paper on a high-throughput screening issue that everyone in the field should be aware of: metal impurities in your compounds. The group (from Roche) describes a recent experience, and I think that many readers will shiver in recognition: The hits were resynthesized, and close analogues were prepared for early structure−activity rel… Read More
  • Drug Assays

    How Many Good Screening Compounds Are There?

    So, how many good screening compounds are there to be had? We can now start to argue about the definition of “good”; that’s the traditional next step in this process. But there’s a new paper from Australia’s Jonathan Baell on this very question that’s worth a look. He and his co-workers have already called attent… Read More
  • Drug Assays

    Four Million Compounds to Screen

    There’s a new paper out that does something unique: it compares the screening libraries of two large drug companies, both of which agreed to open their books to each other (up to a point) for the exercise. The closest analog that I know of is when Bayer merged with/bought Schering AG, and the companies published… Read More
  • Drug Assays

    A Broadside Against The Way We Do Things Now

    There’s a paper out in Drug Discovery Today with the title “Is Poor Research the Cause of Declining Productivity in the Drug Industry? After reviewing the literature on phenotypic versus target-based drug discovery, the author (Frank Sams-Dodd) asks (and has asked before): The consensus of these studies is that drug discovery based on t… Read More
  • Drug Assays

    Roche Repurposes

    Another drug repurposing initiative is underway, this one between Roche and the Broad Institute. The company is providing 300 failed clinical candidates to be run through new assays, in the hopes of finding a use for them. I hope something falls out of this, because any such compounds will naturally have a substantial edge in… Read More
  • Academia (vs. Industry)

    Advice For Those Trying High-Throughput Screening

    So here’s a question that a lot of people around here will have strong opinions on. I’ve heard from someone in an academic group that’s looking into doing some high-throughput screening. As they put it, they don’t want to end up as “one of those groups”, so they’re looking for advice on how to get… Read More
  • Chemical News

    Think Your Drug Is Strange-Looking? Beat This.

    We have a late entry in this year’s “Least Soluble Molecule – Dosed In Vivo Division” award. Try feeding that into your cLogP program and see what it tells you about its polarity. (This would be a good ChemDraw challenge, too). What we’re looking at, I’d say, is a sort of three-dimensional asphalt, decorated arou… Read More
  • Drug Assays

    How Do Chemist (Think That They) Judge Compounds?

    There’s an interesting paper out in PLoS One, called “Inside the Mind of a Medicinal Chemist“. Now, that’s not necessarily a place that everyone wants to go – mine is not exactly a tourist trap, I can tell you – but the authors are a group from Novartis, so they knew what they were getting… Read More
  • Drug Assays

    What’s A Phenotypic Screen, And What Isn’t?

    The recent entry here on a phenotypic screen got some discussion going in the comments, and I thought I’d bring that out here for more. Some readers objected to the paper being characterized as a phenotypic screen at all, saying that it was just a cell-based screen. That got me to thinking about how I… Read More
  • Cancer

    A Good Example of Phenotypic Screening

    I like to highlight phenotypic screening efforts here sometimes, because there’s evidence that they can lead to drugs at a higher-than-usual rate. And who couldn’t use some of that? Here’s a new example from a team at the Broad Institute. They’re looking at the very popular idea of “cancer stem cells” (CSCs), a p… Read More